Alpha Tau Medical (DRTS) Is Down 5.7% After Early-Stop Success In Alpha DaRT Combo Trial

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee

ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

Alpha Tau to Participate in September Investor Conferences

Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Vistra, Nike to Open Higher

Alpha Tau to Participate in October Investor Conferences

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center